Direxion Daily CSI China Internet Bull 2X Shares vs BIO-TECHNE Corp — how do they compare? Direxion Daily CSI China Internet Bull 2X Shares trades at $18.26 (market cap $176.60M), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: BIO-TECHNE Corp is far larger — about 64.4× Direxion Daily CSI China Internet Bull 2X Shares's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Direxion Daily CSI China Internet Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Direxion Daily CSI China Internet Bull 2X Shares for 24 Days and BIO-TECHNE Corp for 63 Days on average.
| CWEB | TECH | |
|---|---|---|
Market Cap | $176.60M | $11.37B |
Volume | 440,349 | 3,153,511 |
Sector | Leveraged / Inverse | Health |
52-Week High | $55.62 | $72.61 |
52-Week Low | $17.39 | $43.31 |
Typical Hold Time | 24 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Signals from Pluang's Aura AI — not financial advice
CWEB trades at $18.02, down 1.85% today amid bearish technical signals. The stock shows weak momentum with all 13 moving averages signaling sell, though oscillators are neutral. Recent news highlights China's AI ambitions and potential for China growth stocks to surge, providing thematic catalysts. Financial ratios remain undisclosed in current data.
Outlook hinges on China's tech sector recovery and AI growth narrative. Risks include geopolitical tensions and market volatility. The upcoming dividend of $0.07 in September 2026 offers income potential, but investors need clarity on fundamentals for sustained upside.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
CWEB is a leveraged ETF that seeks to provide two times (2x) the daily performance of the CSI China Internet Index. It offers magnified exposure to top Chinese internet companies listed on US and Hong Kong exchanges.
Read more on CWEB →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →